Ozempic (semaglutide) was approved by the FDA in December 2017 for type 2 diabetes, and in 2021 the company introduced a higher-dose version of semaglutide, branded as Wegovy, that was approved specifically for weight management
Access to Comprehensive Resources Medical weight loss programs provide a wealth of resources, including personalized nutrition plans, regimens to increase physical activity, and behavioral counseling
Nausea, Vomiting, and Diarrhea Many people experience digestive issues, especially when starting the medication or increasing doses
Massive obesity market opportunity Growing diabetes prevalence globally Potential cardiovascular benefits Expanding applications beyond weight loss Strong commercial performance from current market leaders The success of Ozempic, Wegovy, Mounjaro, and Zepbound has demonstrated that obesity treatment is no longer a niche categoryit is becoming one of the most important therapeutic areas in modern medicine
Daily exposure to pollution, stress, and unhealthy lifestyle habits can increase free radical damage
231 TrueH